Beginning October 1, 2024, AstraZeneca will require all covered entities to submit 340B claims utilization data to ESP™ as a pre-requisite for designating a single contract pharmacy.  This announcement, released on September 9, 2024, clarifies that all data must be submitted within 45 days of the dispense date.  Otherwise, AstraZeneca’s current contract pharmacy policy remains unchanged, including the exclusion of oncology and specialty drugs from the policy.  Unlike many of its manufacturer counterparts, AstraZeneca continues to apply its restrictions in Arkansas, Louisiana, and other states that have passed laws protecting contract pharmacy arrangements.  Covered entities that have already designated a contract pharmacy on the ESP™ platform do not need to do so again.

The Powers 340B team will continue to monitor manufacturers’ restrictive contract pharmacy policies.